Clinical Cancer Research, Vol 2, Issue 11 1837-1842, Copyright © 1996 by American Association for Cancer Research

ARTICLES

A melanosomal membrane protein is a cell surface target for melanoma therapy

Y Takechi, I Hara, C Naftzger, Y Xu and AN Houghton
The Swim Across America Laboratory, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY 10021, USA.

Differentiation antigens on cancer cells are recognized by the immune system. A prototype set of these autoantigens in melanoma cells are the melanosomal glycoproteins, expressed in both melanomas and normal melanocytes. These are intracellular proteins that can be recognized by both antibodies and T lymphocytes. While one can understand how T cells can respond to intracellular proteins, based on cellular requirements for antigen processing and presentation, it is more difficult to understand how antibody responses to melanosomal proteins could lead to tumor rejection. We demonstrate that gp75 is expressed on the cell surface as well as intracellularly in human and mouse melanomas. The surface expression of gp75 can be augmented by IFN-gamma and during tumor growth in vivo. Surface expression of gp75 on mouse melanoma cells correlates with the ability of a monoclonal antibody (mAb) against gp75 to reject melanomas in syngeneic mice. Antibody-mediated rejection seems to require the Fc portion of the antibody, suggesting a role for Fc receptor-positive effector cells such as natural killer cells. However, although NK1.1(+) cells have been implicated in antibody-induced rejection in vivo, cell surface expression of gp75(+) on melanoma does not lead to susceptibility to antibody-dependent cellular cytotoxicity in vitro. The mAb to gp75 induced tumor rejection in mice carrying both scid and bg/bg traits, showing that neither thymus-dependent T cells nor natural killer cytotoxic activity was required in vivo. Long-term treatment of mice with mAb led to patchy depigmentation in the coat. In summary, an intracellular organellar protein can be expressed at the cell surface and provide an antigenic target for antibody therapy and autoimmunity.

This article has been cited by other articles:

				A. K. Simon, T. Newsom-Davis, M. E. F. Frayne, P. F.-T. Ch'en, A. J. McMichael, and G. R. Screaton Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand Int. Immunol., April 1, 2008; 20(4): 525 - 534. [Abstract] [Full Text] [PDF]

				H. A. Doyle, J. Zhou, M. J. Wolff, B. P. Harvey, R. M. Roman, R. J. Gee, R. A. Koski, and M. J. Mamula Isoaspartyl Post-translational Modification Triggers Anti-tumor T and B Lymphocyte Immunity J. Biol. Chem., October 27, 2006; 281(43): 32676 - 32683. [Abstract] [Full Text] [PDF]

				L. Bevaart, M. J.H. Jansen, M. J. van Vugt, J. S. Verbeek, J. G.J. van de Winkel, and J. H.W. Leusen The High-Affinity IgG Receptor, Fc{gamma}RI, Plays a Central Role in Antibody Therapy of Experimental Melanoma Cancer Res., February 1, 2006; 66(3): 1261 - 1264. [Abstract] [Full Text] [PDF]

				A. Slominski, D. J. Tobin, S. Shibahara, and J. Wortsman Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation Physiol Rev, October 1, 2004; 84(4): 1155 - 1228. [Abstract] [Full Text] [PDF]

				R. Niwa, E. Shoji-Hosaka, M. Sakurada, T. Shinkawa, K. Uchida, K. Nakamura, K. Matsushima, R. Ueda, N. Hanai, and K. Shitara Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma Cancer Res., March 15, 2004; 64(6): 2127 - 2133. [Abstract] [Full Text] [PDF]

				A. B. van Spriel, H. H. van Ojik, A. Bakker, M. J. H. Jansen, and J. G. J. van de Winkel Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma Blood, January 1, 2003; 101(1): 253 - 258. [Abstract] [Full Text] [PDF]

				I. C. Le Poole, A. I. Riker, M. E. Quevedo, L. S. Stennett, E. Wang, F. M. Marincola, W. M. Kast, J. K. Robinson, and B. J. Nickoloff Interferon-{gamma} Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells Am. J. Pathol., February 1, 2002; 160(2): 521 - 528. [Abstract] [Full Text] [PDF]

				H.-M. Hu, H. Winter, W. J. Urba, and B. A. Fox Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy J. Immunol., October 15, 2000; 165(8): 4246 - 4253. [Abstract] [Full Text] [PDF]

				R. Dyall, W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic Heteroclitic Immunization Induces Tumor Immunity J. Exp. Med., November 2, 1998; 188(9): 1553 - 1561. [Abstract] [Full Text] [PDF]

				R. Clynes, Y. Takechi, Y. Moroi, A. Houghton, and J. V. Ravetch Fc receptors are required in passive and active immunity to melanoma PNAS, January 20, 1998; 95(2): 652 - 656. [Abstract] [Full Text] [PDF]